Next Article in Journal
Collembola (Hexapoda) as Biological Drivers between Land and Sea
Previous Article in Journal
Molecular Mechanisms of Borrelia burgdorferi Phagocytosis and Intracellular Processing by Human Macrophages
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biology
Volume 10
Issue 7
10.3390/biology10070566
biology-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients

by
Sherihan AbdelHamid
1,*,
Hala El-Mesallamy
1,2,
Hany Abdel Aziz
3 and
Abdel-Rahman Zekri
4
1
Department of Biochemistry, Faculty of Pharmacy, Ain Shams University, Cairo 11566, Egypt
2
Dean of Faculty of Pharmacy, Sinai University, North Sinai 45518, Egypt
3
Department of Clinical Oncology, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt
4
Virology and Immunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Giza 11796, Egypt
*
Author to whom correspondence should be addressed.
Biology 2021, 10(7), 566; https://doi.org/10.3390/biology10070566
Submission received: 18 May 2021 / Revised: 7 June 2021 / Accepted: 17 June 2021 / Published: 22 June 2021
(This article belongs to the Section Biochemistry and Molecular Biology)
Browse Figures
Versions Notes

Abstract

:

Simple Summary

Countries with emerging economies suffer from a high incidence of breast cancer and advanced stage at diagnosis, coupled with limited health and medical care resources. Egypt has witnessed the world’s oldest documented cancer case, more than 3500 years BC, and the Egyptian population shows a high degree of genetic diversity compared to other populations due to its complex and diverse ethnic origins, with high incidence and mortality rates of breast cancer. Though the incidence and profile of BRCA1/2 mutations is population specific, data on population-based clinical outcomes are scarce. In this context, this study is an attempt to elucidate the long-term prognostic implications of BRCA1/2 mutations in Egyptian female breast cancer patients over 24 years. We believe that our findings provide indicators to implement screening strategies as well as optimize treatment options and prophylactic measures for BRCA1/2 carriers that can be applied in the routine clinical practice.

Abstract

Evidence on the prognostic relevance of BRCA1/2 mutations on breast cancer survival is still debatable. To address this ambiguity, we sought to elucidate the impact of BRCA1/2 mutation carriership on long-term clinical outcomes for the first time in Egyptian female breast cancer patients. This study comprised 103 Egyptian female breast cancer patients previously tested for BRCA1/2 mutations. Clinicopathological characteristics and long-term follow-up data were retrieved from clinical records until death or loss to follow-up. Overall survival (OS), recurrence-free survival (RFS), disease-free survival (DFS), and metastasis-free survival (MFS) were compared in BRCA1/2 mutation carriers and non-carriers. Pathogenic variants (Class 5 according to ACMG/AMP guidelines) were observed in 29 cases. The profile of the detected variants was previously reported. After median follow-up time of 6.9 years (range, 4.2–24.4 years), BRCA1/2 carriers exhibited significantly worse RFS compared to non-carriers (p = 0.01; HR = 3.00 (95%CI 1.35–6.68)). However, we couldn’t demonstrate statistically significant difference between carriers of pathogenic mutations and non-carriers regarding MFS (p = 0.24; HR = 1.38 (95%CI 0.8–2.4)), DFS (p = 0.11; HR = 1.23 (95%CI 0.74–2.06)), or OS (p = 0.36; HR = 1.23 (95%CI 0.58–2.61)). Though no significant impact was observed in OS, yet BRCA1/2 mutation carriers were at high risk of recurrence, highlighting the importance of adopting BRCA screening strategies and prophylactic measures.

1. Introduction

Breast cancer is the most commonly occurring cancer in females and the leading cause of global cancer-related mortality [1,2]. Its marked impact is shifting gradually to the developing world and may even exceed that of Western industrialized societies in the near future [3,4]. These countries of emerging economies suffer from high incidence of breast cancer and advanced stage at diagnosis, coupled with limited health and medical care resources [5].
Molecular genetic studies have elucidated breast-cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) as two major predisposing genes for breast cancer [6]. Inherited BRCA1 and BRCA2 mutations are associated with increased lifetime risks of breast and ovarian cancers by 45–75% and 18–40%, respectively [7,8,9,10], as well as other cancers like pancreatic and prostate cancers [11].
In addition to the established predictive importance of BRCA1/2 mutation status in evaluating breast cancer risk [12,13], the identification of carriers of BRCA1/2 mutations has significant implications in guiding surgical, radiotherapeutic, and drug treatment options [14,15]. Emerging research studies have demonstrated the clinical significance of BRCA1/2 mutation status in predicting the response to chemotherapy [16] and poly(ADP-ribose) polymerase (PARP) inhibitors [17,18].
Moreover, BRCA1/2 mutations have been studied as markers of pathological aggressiveness, with BRCA1-mutated tumors usually being of high histological grade at diagnosis, poorly differentiated, and triple negative, whereas BRCA2-related tumors are on average of high grade than non-carriers [19,20,21]. These unique histopathological features support the notion that BRCA1/2 mutation carriers may have different prognosis in comparison to sporadic cases [22,23].
Nonetheless, the prognostic significance of BRCA1/2 mutational status on breast cancer survival is still debatable. Few published clinical studies have found that breast cancer patients with BRCA1/2 mutations show better prognosis than control groups [24,25], while others have reported that they have worse survival outcomes [26,27,28], whereas some studies reported similar prognosis [29,30,31,32,33]. This disparity might be attributed to discrepancies in methodological issues (including study size, design, studied populations), relatively low incidence of the BRCA1/2 mutations, lack of adjustments for clinical variables, including risk-reducing options or treatment strategies, and short follow-up.
Previous studies have shown possible molecular, clinical, and epidemiological differences in breast cancer worldwide [34,35,36]. Though the incidence and profile of BRCA1/2 mutations is population specific, data on clinical outcomes in different populations are scarce and most of the conducted studies included data on white patients, thereby potentially underestimating differences pertinent to genetic defects. These data highlight the need to elucidate the effect of BRCA1/2 mutations on breast cancer prognosis in different populations, as this can impact future risk assessment and treatment planning. To our knowledge, sparse clinical data have been published in the Middle East to substantiate this assertion.
We previously reported the profile of BRCA1/2 mutations in a cohort of 103 Egyptian female breast cancer patients who were not selected on the basis of age at onset of breast cancer or family history [37]. This study was conducted to elucidate the clinicopathological characteristics and the prognostic relevance of BRCA1/2 mutations on long-term survival outcome in Egyptian female breast cancer patients. These findings will help to improve treatment options and surveillance policies for breast cancer patients harboring BRCA1/2 mutations.

2. Materials and Methods

2.1. Data Collection and Ethical Statement

A cohort of 103 Egyptian female patients diagnosed with primary invasive breast cancer were retrospectively included in the study. The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethical Committee of Ain Shams University, Egypt.
Clinicopathological and demographic data were extracted from hospital medical records including age at primary breast cancer diagnosis, age at menarche, menopausal status at diagnosis, marital status, parity, the use of hormonal contraception, age at first full-term pregnancy and nursing. Family history of cancer and familial relationships between family members with cancer was collected by questionnaire. Tumor characteristics with regard to pathological stage, tumor size, nodal involvement, evidence of metastasis, histological type, estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER-2) status, and type of surgery performed were collected from the pathology and medical records.
Follow-up data regarding date of diagnosis, clinical treatment details, the course of the disease, as well as site of disease progression (recurrence or metastatic disease), if any, were retrieved from medical records until death or loss to follow-up. The date of last follow-up assessment was retrieved from the medical records and through the treating physician, via telephone contact with the patient or her next-of-kin.

2.2. Mutational Analysis

BRCA1/2 mutations were tested using HRM analysis and direct sequencing as previously described [37]. DNA was extracted from whole blood samples collected at the time of patient recruitment. The detected variants were classified according to the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) guidelines.

2.3. Outcomes Measures

Patients were followed from the date they were diagnosed with primary invasive breast cancer until the last follow-up date (the last date at which the patients were seen alive or free of the disease) or until death. The OS was calculated as the time from date of diagnosis until the date of death from any cause or last follow up. The RFS was defined as the time from date of surgery until the date of any loco-regional recurrence, contralateral breast tumor, death, or last follow-up. The DFS was determined as the time from date of surgery until the date of recurrence, distant metastasis, death, or last follow-up. The MFS was defined as time from date of surgery until the date of any distant metastasis, death, or last follow-up.

2.4. Statistical Analysis

The clinicopathologic characteristics were compared according to BRCA mutation status using Chi-squared test for categorical variables and t test for continuous variables. Multivariate logistic regression was used to determine the factors predictive of BRCA1/2 mutations. The log-rank test was used to perform comparisons between groups. The independent association of mutation status with outcome was determined using Cox proportional hazards regression analysis. Hazard ratios (HR) and their 95% confidence intervals (CI) for multivariable analyses were estimated. A p ≤ 0.05 was considered statistically significant. Statistical analysis was performed using IBM© SPSS© Statistics version 26 (IBM© Corp., Armonk, NY, USA).

3. Results

3.1. Demographic and Clinicopathological Characteristics of the Study Cohort

In total, BRCA1/2 variants were detected in 46 patients; 29 patients were carriers of BRCA1/2 pathogenic variants (ACMG/AMG Class 5). The profile of the detected mutations was previously reported [37]. The majority of patients (91.3%) were treated with modified radical mastectomy (MRM). More than 70% of cases have received adjuvant chemotherapy: cyclophosphamide, methotrexate, and fluorouracil (CMF) regimen; or flourouracil, adriamycin, cyclophosphamide (FAC) regimen. In addition, 71.8% of cases have received hormonal therapy. The clinicopathological characteristics of the cohort are shown in Table 1.
Median ages at diagnosis were 40 years (range, 24–57 years) in BRCA1/2 carriers of pathogenic variants and 48 years (range, 39–66 years) in BRCA non-carriers (p = 0.008). In comparison to non-carriers, BRCA1/2 carriers were more likely to have early onset breast cancer (48% versus 28%, p = 0.05), to be premenopausal at the time of diagnosis (82% vs. 54%, p = 0.02), and to have family history of breast cancer (45% vs. 35%, p = 0.024). BRCA1/2 carriers were also more likely to have positive family history of any cancer (OR: 3.969, 95%CI (1.623–9.71), p = 0.002). There was no statistically significant difference with respect to the median ages of menarche, first full-term pregnancy, parity, nursing, or the use of hormonal contraception. Positive lymph node metastasis was more frequently observed in BRCA1/2 carriers (76% vs. 53%, p = 0.03). No statistical significance was observed in tumor size. The majority of patients had grade II invasive ductal carcinoma. The incidence of ER-negative, PR-negative and HER-2 negative tumors was higher in BRCA1/2 carriers versus non carriers (28% vs. 22%, 38% vs. 30%, 76% vs. 67%, respectively) though not statistically significant. Multivariate logistic regression model in all carriers revealed that age at diagnosis (p =0.047), positive lymph node involvement (p = 0.05), family history of any cancer (p = 0.051, borderline) remained statistically independent predictors for BRCA1/2 mutations. More than 70% of cases have received adjuvant chemotherapy: cyclophosphamide, methotrexate, and fluorouracil (CMF) regimen; or flourouracil, adriamycin, cyclophosphamide (FAC) regimen. In addition, 71.8% of cases have received hormonal therapy.
When we compared BRCA1 or BRCA2 independently versus non-carriers, BRCA1 carriers were found to be diagnosed at younger age than non-carriers (p = 0.006). Both BRCA1 and BRCA2 carriers tended to be premenopausal at time of diagnosis (p = 0.05). In comparison to non-carriers, 63% of BRCA1 positive cases reported family history of breast cancer and 56% of BRCA2 cases had family history of other cancers (p = 0.001). BRCA2 carriers were more likely to have positive regional lymph node metastasis than non-carriers (p = 0.012). There was no significant difference regarding tumor size, histological type, grade, hormone receptor status or the presence of bilateral breast cancers between BRCA1 or BRCA2 carriers and non-carriers.

3.2. Prognosis of BRCA1/2 Mutation Carriers and Non-Carriers

3.2.1. BRCA1/2 Carriers of Pathogenic Variants

As shown in Figure 1, BRCA1/2 carriers of pathogenic mutations exhibited significantly worse RFS in comparison to non-carriers (p = 0.01; HR = 3.00 (95%CI 1.35–6.68)). Though there was a trend toward worse MFS and DFS in BRCA1/2 carriers compared to non-carriers, but the difference was not statistically significant (p = 0.24; HR = 1.38 (95%CI 0.8–2.4) and p = 0.11; HR = 1.23 (95%CI 0.74–2.06), respectively). Similarly, the difference in OS in BRCA1/2 carriers versus non-carriers didn’t reach statistical significance (p = 0.36; HR = 1.23 (95%CI 0.58–2.61)).

3.2.2. All BRCA1/2 Mutation Carriers

When we compared the survival outcomes in carriers of all BRCA1/2 variants to non-carriers, BRCA1/2 carriers exhibited worse DFS than non-carriers: at two years 86% vs. 88%; at five years 38% vs. 58%; and at 10 years 22% vs. 34% (p = 0.04; HR = 2 [95%CI 1.1–2.4]) (Figure 2). As shown in Table 2, univariate analysis revealed that, in addition to BRCA mutation status, ER-, PR-negative receptor status, bilateral breast cancer, and large tumor size (T3–T4) were associated with worse DFS. However, stepwise cox proportional regression analysis showed that only ER-negative receptor (HR = 2.44 (95%CI = 1.33–4.47); p = 0.004) and large tumor size (HR = 2.19 (HR = 1.21–3.98); p = 0.01) were the only variables that independently affected DFS. The RFS was significantly worse in all carriers compared to non-carriers. The RFS at two years was 94%vs 98%; at five years: 50% vs. 84%; and at 10 years 34% vs. 60% (p = 0.005, HR = 2.53 (95%CI 1.3–4.92)). However, as shown in Figure 2, no statistical difference was noted in OS (p = 0.42; HR = 1.32 (95%CI 0.66–2.62)) or MFS (p = 0.41; HR = 1.25 (95%CI 0.74–2.11)), where OS was 82%, 59%, and 36% vs. 94%, 60%, and 59% at five, 10, and 15 years in carriers versus non-carriers, respectively. While MFS in all carriers versus non carriers was 87%, 45%, and 25% vs. 88%, 62%, and 38% at two, five, and 10 years, respectively.

3.2.3. BRCA1 and BRCA2 Carriers Independently

No statistically significant difference was detected between carriers of BRCA1 or BRCA2 pathogenic mutations when analyzed independently with regards to RFS (p = 0.27; HR = 1.71 (95%CI 0.79–3.7); MFS (p = 0.64; HR = 1.38 (95%CI 0.78–2.44)); DFS (p = 0.74; HR = 1.38 (95%CI 0.8–2.36)) or OS (p = 0.09; HR = 1.36, (95%CI 0.62–2.98)) (Figure 3).

3.2.4. BRCA1 Mutation c.5205delA

As previously reported [37], this pathogenic mutation was detected in high frequency in our cohort. Hence, we sought to analyze the clinicopathological characteristics and survival outcome in the patients harboring this mutation in comparison to non-carriers. However, no significant difference was detected except for young age at diagnosis (p = 0.036). The association of this mutation with OS, DFS, RFS, or DFS did not reach statistical significance (Table 3).

4. Discussion

Besides their impact on the susceptibility to breast cancer, BRCA1/2 mutations may be linked to distinctive clinical course and biological features. We sought to retrospectively evaluate the impact of the BRCA1/2 variants that were previously detected in this cohort, on the long-term survival outcomes over 24 years (1997–2019).
In this population-based retrospective study, the median follow-up period was 6.9 years (range, 4.2–24.4 years). BRCA1/2 carriers exhibited significantly worse RFS than non-carriers, with three-fold increased risk of contralateral breast cancer or locoregional recurrence. This finding is in broad agreement with results of other studies. For instance, Verhoog et al. showed that the development of contralateral breast cancer was 4–5 times more frequent in BRCA1 mutation carriers than in the sporadic patients [38]. Bordeleau and colleagues also reported a 10-year increased risk of contralateral breast cancers of 20–40% in BRCA mutation carriers [31]. By the age of 70 years, BRCA1 and BRCA2 carriers were previously found to have average cumulative risk of contralateral breast cancer of 83% and 62%, respectively [10]. Ye et al. also showed higher risk of contralateral breast cancer in BRCA mutation carriers [39].
Nonetheless, no difference in DFS was noted between carriers of pathogenic variants in this study and non-carriers, although carriers of all BRCA1/2 variants showed slightly worse DFS that could not independently predict survival. A recent study by Vocka et al. [40] recently reported slightly worse DFS in carriers of BRCA1/2 mutations, whereas a meta-analysis by van den Broek et al. [26] showed that BRCA1/BRCA2 mutation carriers had a non-significant tendency towards poorer survival.
Furthermore, our results did not reveal a statistically significant difference between BRCA1/2 mutation carriers and non-carriers regarding MFS or OS. Some studies showed worse OS in patients with BRCA1 mutations compared to sporadic cases [41,42]. Schmidt et al. reported that BRCA1/2 mutation carriers who were diagnosed with breast cancer before the age of 50 years had worse OS that may be attributed to differences in tumor features, response to treatment, and secondary cancers [28]. Similarly, BRCA1 mutation only was previously shown to decrease the OS and progression-free survival [43]. Besides, a metanalysis by Barretta and colleagues, including 105,220 breast cancer patients from 60 studies, showed worse OS and worse breast cancer specific survival (BCSS) in BRCA1 mutation carriers while BRCA2 carriers had worse BCSS only in comparison to sporadic cases [27]. However, other reports revealed similar survival outcome in both mutation carriers and non-carriers [31,38,44,45,46,47]. Systematic reviews with meta-analysis of survival outcome in BRCA1 or BRCA2 mutation carriers and non-carriers showed that current evidence did not support either poorer or better survival of BRCA carriers [26,27,32]. The POSH prospective study also found no significant differences in OS or distant DFS in patients with and without BRCA1 or BRCA2 mutations [48].
BRCA-associated breast cancers have unique clinicopathological characteristics compared to sporadic counterparts. In agreement with previous studies [22,41,49,50], carriers of BRCA1/2 mutations in the current study are characterized by early onset, positive family history of breast cancer, premenopausal state at diagnosis, and positive lymph node involvement. Other reports showed that BRCA-associated tumours are more often ER and PR negative [51,52]. However, though BRCA1/2 mutation carriers in the current study showed higher incidence of negative hormone receptors status than non-carriers, the difference was statistically indistinguishable. Consistent with prior observation [22], HER-2 expression status was similar in patients with and without mutations. Our findings show that early age at diagnosis, lymph node metastasis, and positive family history of any cancer are independent predictors BRCA1/2 mutations, which have important clinical implications for screening and early diagnosis in our population.
As previously reported by Kwong et al. [50], BRCA1 carriers were found to be younger at the time of diagnosis than non-carriers. BRCA2 carriers showed positive family history of other cancers, which may indicate that in addition to breast cancer, BRCA2 mutations may increase the risk of developing other cancers including prostate, pancreatic, pharyngeal, brain cancers and leukemia [53]. Unlike other studies illustrating that BRCA1 mutant tumors feature higher grade, invasive borders and higher proliferation indices; while BRCA2 mutation carriers are more likely to present with ER positive tumors and increased risk of contralateral breast cancer [29,44], however these differences were not noted in the current study. Additionally, we couldn’t demonstrate distinct survival outcomes when assessing the impact of BRCA1 and BRCA2 mutations separately. This finding is in line with the work of Templeton et al., a systematic review and meta-regression study that included 10,180 patients from 16 studies, showing that BRCA1 or BRCA2 mutations independently were not associated with worse OS [33].
The BRCA1 pathogenic mutation c.5205delA was a novel mutation detected for the first time in our cohort (NCBI ClinVar VCV000140168). Patients harboring this mutation were diagnosed at significantly younger age than non-carriers. However, this mutation was not linked to worse survival outcomes.
BRCA mutation status could provide important insights regarding prevention, surveillance, and treatment strategies [15]. Primary prevention measures, including prophylactic mastectomy, chemoprevention, and intensive surveillance, can decrease the risk of breast cancer in BRCA1/BRCA2 mutations [54,55,56]. The standard treatment protocols for BRCA mutation carriers are still debatable. Studies have shown that contralateral mastectomy in breast cancer patients with BRCA1/2 mutations can decrease breast cancer specific mortality [57]. A study including 1504 patients with germline BRCA1 or BRCA2 mutations showed that chemoprevention using tamoxifen is associated with a 50% reduction in the risk for developing contralateral breast cancer [45]. In addition, 10 years of tamoxifen therapy can also reduce the risk of breast cancer recurrence in premenopausal women [58]. Some studies have also shown that BRCA1/2 mutation carriers exhibit different response to chemotherapy [59,60]. Under the precision medicine initiative, tailored treatment strategies including PARP inhibitors can be beneficial to carriers of BRCA1 and BRCA2 mutations [17,18].
The results of this study may unveil the underlying genetic alterations that may be predominating in the disparate population of Egyptian female breast cancer patients that may be linked to clinical characteristics and outcome. Major strengths of the current study are the long follow-up time and the unselected cohort. Nevertheless, study limitations lay in the retrospective study design as the 24-year study period (1997–2019) should have witnessed changes in diagnostic modalities and treatment options. Another limitation is the limited sample size. However, the meta-analysis by Baretta et al. on breast cancer survival in carriers of BRCA1/BRCA2 mutations included 60 studies with the number of mutation carriers ranging from 5 to 326 (median, 39.5) [27]. Further prospective studies on larger cohorts are warranted to ascertain the prognostic significance and clinicopathological differences in BRCA1/2 mutation carriers, aiming to optimize treatment choices and surveillance policies in patients harboring these mutations.

5. Conclusions

To the best of our knowledge, this is the first study in the Middle East to report long-term survival outcome of BRCA1/2 related breast cancer. Based on our findings, BRCA-associated breast cancers showed a high pattern of locoregional recurrence and contralateral breast cancer. Herein, we emphasize the importance of adopting BRCA screening strategies and patient counselling regarding prophylactic measures and tailored treatment options in the mainstream oncology practice in Egypt.

Author Contributions

Conceptualization, S.A., H.E.-M., H.A.A., and A.-R.Z.; data curation, S.A., H.E.-M., H.A.A., and A.-R.Z.; formal analysis, S.A.; investigation, S.A. and H.A.A.; methodology, S.A., H.A.A., and A.-R.Z.; project administration, H.A.A.; resources, S.A.; software, S.A. and A.-R.Z.; supervision, H.E.-M., H.A.A., and A.-R.Z.; validation, H.A.A. and A.-R.Z.; visualization, H.A.A., and A.-R.Z.; writing—original draft, S.A.; writing—review & editing, H.E.-M., H.A.A., and A.-R.Z. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of Ain Shams University, Egypt.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 2019, 69, 7–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Gong, Y.; Ji, P.; Hu, X.; Shao, Z.-M. Abstract P2-08-16: The burden and trends of breast cancer from 1990 to 2017 at the global, regional, and national level: Results from the global burden of disease study 2017. In Proceedings of the 2019 San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 10–14 December 2019. [Google Scholar] [CrossRef]
  3. Li, N.; Deng, Y.; Zhou, L.; Tian, T.; Yang, S.; Wu, Y.; Zheng, Y.; Zhai, Z.; Hao, Q.; Song, D.; et al. Global burden of breast cancer and attributable risk factors in 195 countries and territories, from 1990 to 2017: Results from the Global Burden of Disease Study 2017. J. Hematol. Oncol. 2019, 12, 140. [Google Scholar] [CrossRef]
  4. Winters, S.; Martin, C.; Murphy, D.; Shokar, N.K. Breast Cancer Epidemiology, Prevention, and Screening. In Approaches to Understanding Breast Cancer. Progress in Molecular Biology and Translational Science; Lakshmanaswamy, R., Ed.; Elsevier Academic Press Inc.: San Diego, CA, USA, 2017; Volume 151, pp. 1–32. [Google Scholar]
  5. Tfayli, A.; Temraz, S.; Abou Mrad, R.; Shamseddine, A. Breast Cancer in Low- and Middle-Income Countries: An Emerging and Challenging Epidemic. J. Oncol. 2010, 2010. [Google Scholar] [CrossRef] [PubMed]
  6. Szabo, C.I.; King, M.C. Population genetics of BRCA1 and BRCA2. Am. J. Hum. Genet. 1997, 60, 1013–1020. [Google Scholar]
  7. Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.A.; Mooij, T.M.; Roos-Blom, M.J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA J. Am. Med. Assoc. 2017, 317, 2402–2416. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Antoniou, A.; Pharoah, P.D.P.; Narod, S.; Risch, H.A.; Eyfjord, J.E.; Hopper, J.L.; Loman, N.; Olsson, H.; Johannsson, O.; Borg, A.; et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. Am. J. Hum. Genet. 2003, 72, 1117–1130. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  9. Chen, S.N.; Parmigiani, G. Meta-analysis of BRCA1 and BRCA2 penetrance. J. Clin. Oncol. 2007, 25, 1329–1333. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  10. Mavaddat, N.; Peock, S.; Frost, D.; Ellis, S.; Platte, R.; Fineberg, E.; Evans, D.G.; Izatt, L.; Eeles, R.A.; Adlard, J.; et al. Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE. J. Natl. Cancer Inst. 2013, 105, 812–822. [Google Scholar] [CrossRef] [Green Version]
  11. Cavanagh, H.; Rogers, K.M.A. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered. Cancer Clin. Pract. 2015, 13. [Google Scholar] [CrossRef] [Green Version]
  12. Kwon, J.S.; Gutierrez-Barrera, A.M.; Young, D.; Sun, C.C.; Daniels, M.S.; Lu, K.H.; Arun, B. Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors. J. Clin. Oncol. 2010, 28, 4214–4220. [Google Scholar] [CrossRef] [PubMed]
  13. Begg, C.B.; Haile, R.W.; Borg, A.; Malone, K.E.; Concannon, P.; Thomas, D.C.; Langholz, B.; Bernstein, L.; Olsen, J.H.; Lynch, C.F.; et al. Variation of breast cancer risk among BRCA1/2 carriers. JAMA J. Am. Med. Assoc. 2008, 299, 194–201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Trainer, A.H.; Lewis, C.R.; Tucker, K.; Meiser, B.; Friedlander, M.; Ward, R.L. The role of BRCA mutation testing in determining breast cancer therapy. Nat. Rev. Clin. Oncol. 2010, 7, 708–717. [Google Scholar] [CrossRef] [PubMed]
  15. Tung, N.M.; Garber, J.E. BRCA1/2 testing: Therapeutic implications for breast cancer management. Br. J. Cancer 2018, 119, 141–152. [Google Scholar] [CrossRef]
  16. Caramelo, O.; Silva, C.; Caramelo, F.; Frutuoso, C.; Almeida-Santos, T. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis. Hered. Cancer Clin. Pract. 2019, 17, 11. [Google Scholar] [CrossRef] [Green Version]
  17. Lee, J.M.; Ledermann, J.A.; Kohn, E.C. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Ann. Oncol. 2014, 25, 32–40. [Google Scholar] [CrossRef]
  18. Kaufman, B.; Shapira-Frommer, R.; Schmutzler, R.K.; Audeh, M.W.; Friedlander, M.; Balmana, J.; Mitchell, G.; Fried, G.; Stemmer, S.M.; Hubert, A.; et al. Olaparib Monotherapy in Patients with Advanced Cancer and a Germline BRCA1/2 Mutation. J. Clin. Oncol. 2015, 33, 244–250. [Google Scholar] [CrossRef]
  19. Lakhani, S.R.; Jacquemier, J.; Sloane, J.P.; Gusterson, B.A.; Anderson, T.J.; van de Vijver, M.J.; Farid, L.M.; Venter, D.; Antoniou, A.; Storfer-Isser, A.; et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl. Cancer Inst. 1998, 90, 1138–1145. [Google Scholar] [CrossRef]
  20. Honrado, E.; Osorio, A.; Palacios, J.; Benitez, J. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 2006, 25, 5837–5845. [Google Scholar] [CrossRef] [PubMed]
  21. Southey, M.C.; Ramus, S.J.; Dowty, J.G.; Smith, L.D.; Tesoriero, A.A.; Wong, E.E.M.; Dite, G.S.; Jenkins, M.A.; Byrnes, G.B.; Winship, I.; et al. Morphological predictors of BRCA1 germline mutations in young women with breast cancer. Br. J. Cancer 2011, 104, 903–909. [Google Scholar] [CrossRef] [PubMed]
  22. Atchley, D.P.; Albarracin, C.T.; Lopez, A.; Valero, V.; Amos, C.I.; Gonzalez-Angulo, A.M.; Hortobagyi, G.N.; Arun, B.K. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J. Clin. Oncol. 2008, 26, 4282–4288. [Google Scholar] [CrossRef]
  23. Mavaddat, N.; Barrowdale, D.; Andrulis, I.L.; Domchek, S.M.; Eccles, D.; Nevanlinna, H.; Ramus, S.J.; Spurdle, A.; Robson, M.; Sherman, M.; et al. Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol. Biomark. Prev. 2012, 21, 134–147. [Google Scholar] [CrossRef] [Green Version]
  24. Maksimenko, J.; Irmejs, A.; Nakazawa-Miklasevica, M.; Melbarde-Gorkusa, I.; Trofimovics, G.; Gardovskis, J.; Miklasevics, E. Prognostic role of BRCA1 mutation in patients with triple-negative breast cancer. Oncol. Lett. 2014, 7, 278–284. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Cortesi, L.; Masini, C.; Cirilli, C.; Medici, V.; Marchi, I.; Cavazzini, G.; Pasini, G.; Turchetti, D.; Federico, M. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer. BMC Cancer 2010, 10. [Google Scholar] [CrossRef] [Green Version]
  26. van den Broek, A.J.; Schmidt, M.K.; van’t Veer, L.J.; Tollenaar, R.; van Leeuwen, F.E. Worse Breast Cancer Prognosis of BRCA1/BRCA2 Mutation Carriers: What’s the Evidence? A Systematic Review with Meta-Analysis. PLoS ONE 2015, 10, 29. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  27. Baretta, Z.; Mocellin, S.; Goldin, E.; Olopade, O.I.; Huo, D. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine 2016, 95. [Google Scholar] [CrossRef]
  28. Schmidt, M.K.; van den Broek, A.J.; Tollenaar, R.; Smit, V.; Westenend, P.J.; Brinkhuis, M.; Oosterhuis, W.J.W.; Wesseling, J.; Janssen-Heijnen, M.L.; Jobsen, J.J.; et al. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. JNCI J. Natl. Cancer Inst. 2017, 109, 10. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Brekelmans, C.T.M.; Tilanus-Linthorst, M.M.A.; Seynaeve, C.; Van der Ouweland, A.; Menke-Pluymers, M.B.E.; Bartels, C.C.M.; Kriege, M.; van Geel, A.N.; Burger, C.W.; Eggermont, A.M.M.; et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur. J. Cancer 2007, 43, 867–876. [Google Scholar] [CrossRef]
  30. Rennert, G.; Bisland-Naggan, S.; Barnett-Griness, O.; Bar-Joseph, N.; Zhang, S.Y.; Rennert, H.S.; Narod, S.A. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med. 2007, 357, 115–123. [Google Scholar] [CrossRef] [Green Version]
  31. Bordeleau, L.; Panchal, S.; Goodwin, P. Prognosis of BRCA-associated breast cancer: A summary of evidence. Breast Cancer Res. Treat. 2010, 119, 13–24. [Google Scholar] [CrossRef]
  32. Zhong, Q.; Peng, H.L.; Zhao, X.; Zhang, L.; Hwang, W.T. Effects of BRCA1- and BRCA2-Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis. Clin. Cancer Res. 2015, 21, 211–220. [Google Scholar] [CrossRef] [Green Version]
  33. Templeton, A.J.; Gonzalez, L.D.; Vera-Badillo, F.E.; Tibau, A.; Goldstein, R.; Seruga, B.; Srikanthan, A.; Pandiella, A.; Amir, E.; Ocana, A. Interaction between Hormonal Receptor Status, Age and Survival in Patients with BRCA1/2 Germline Mutations: A Systematic Review and Meta-Regression. PLoS ONE 2016, 11, e0154789. [Google Scholar] [CrossRef] [PubMed]
  34. Momenimovahed, Z.; Salehiniya, H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer Targets Ther. 2019, 11, 151–164. [Google Scholar] [CrossRef] [Green Version]
  35. Sopik, V. International variation in breast cancer incidence and mortality in young women. Breast Cancer Res. Treat. 2021, 186, 497–507. [Google Scholar] [CrossRef] [PubMed]
  36. Hortobagyi, G.N.; de la Garza Salazar, J.; Pritchard, K.; Amadori, D.; Haidinger, R.; Hudis, C.A.; Khaled, H.; Liu, M.C.; Martin, M.; Namer, M.; et al. ABREAST Investigators. The global breast cancer burden: Variations in epidemiology and survival. Clin. Breast Cancer 2005, 5, 391–401. [Google Scholar] [CrossRef] [PubMed]
  37. AbdelHamid, S.G.; Zekri, A.N.; AbdelAziz, H.M.; El-Mesallamy, H.O. BRCA1 and BRCA2 truncating mutations and variants of unknown significance in Egyptian female breast cancer patients. Clin. Chim. Acta 2021, 512, 66–73. [Google Scholar] [CrossRef] [PubMed]
  38. Verhoog, L.C.; Brekelmans, C.T.M.; Seynaeve, C.; van den Bosch, L.M.C.; Dahmen, G.; van Geel, A.N.; Tilanus-Linthorst, M.M.A.; Bartels, C.C.M.; Wagner, A.; van den Ouweland, A.; et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 1998, 351, 316–321. [Google Scholar] [CrossRef]
  39. Ye, F.G.; Huang, L.; Lang, G.T.; Hu, X.; Di, G.H.; Shao, Z.M.; Cao, A.Y. Outcomes and risk of subsequent breast events in breast-conserving surgery patients with BRCA1 and BRCA2 mutation. Cancer Med. 2020, 9, 1903–1910. [Google Scholar] [CrossRef]
  40. Vocka, M.; Zimovjanova, M.; Bielcikova, Z.; Tesarova, P.; Petruzelka, L.; Mateju, M.; Krizova, L.; Kotlas, J.; Soukupova, J.; Janatova, M.; et al. Estrogen Receptor Status Oppositely Modifies Breast Cancer Prognosis in BRCA1/BRCA2 Mutation Carriers Versus Non-Carriers. Cancers 2019, 11, 17. [Google Scholar] [CrossRef] [Green Version]
  41. Wang, Y.A.; Jian, J.W.; Hung, C.F.; Peng, H.P.; Yang, C.F.; Cheng, H.C.S.; Yang, A.S. Germline breast cancer susceptibility gene mutations and breast cancer outcomes. BMC Cancer 2018, 18, 13. [Google Scholar] [CrossRef] [Green Version]
  42. Stoppa-Lyonnet, D.; Ansquer, Y.; Dreyfus, H.; Gautier, C.; Gauthier-Villars, M.; Bourstyn, E.; Clough, K.B.; Magdelenat, H.; Pouillart, P.; Vincent-Salomon, A.; et al. Familial invasive breast cancers: Worse outcome related to BRCA1 mutations. J. Clin. Oncol. 2000, 18, 4053–4059. [Google Scholar] [CrossRef] [PubMed]
  43. Lee, E.H.; Park, S.K.; Park, B.; Kim, S.W.; Lee, M.H.; Ahn, S.H.; Son, B.H.; Yoo, K.Y.; Kang, D.; Grp, K.R.; et al. Effect of BRCA1/2 mutation on short-term and long-term breast cancer survival: A systematic review and meta-analysis. Breast Cancer Res. Treat. 2010, 122, 11–25. [Google Scholar] [CrossRef]
  44. Goodwin, P.J.; Phillips, K.A.; West, D.W. Prognosis of breast cancer in carriers of BRCA1 and BRCA2 mutations. N. Engl. J. Med. 2007, 357, 1555. [Google Scholar] [PubMed]
  45. Gronwald, J.; Robidoux, A.; Kim-Sing, C.; Tung, N.; Lynch, H.T.; Foulkes, W.D.; Manoukian, S.; Ainsworth, P.; Neuhausen, S.L.; Demsky, R.; et al. Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 2014, 146, 421–427. [Google Scholar] [CrossRef]
  46. Lee, L.J.; Alexander, B.; Schnitt, S.J.; Comander, A.; Gallagher, B.; Garber, J.E.; Tung, N. Clinical Outcome of Triple Negative Breast Cancer in BRCA1 Mutation Carriers and Noncarriers. Cancer 2011, 117, 3093–3100. [Google Scholar] [CrossRef] [Green Version]
  47. Huzarski, T.; Byrski, T.; Gronwald, J.; Gorski, B.; Domagala, P.; Cybulski, C.; Oszurek, O.; Szwiec, M.; Gugala, K.; Stawicka, M.; et al. Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer. J. Clin. Oncol. 2013, 31, 3191–3196. [Google Scholar] [CrossRef] [PubMed]
  48. Copson, E.R.; Maishman, T.C.; Tapper, W.J.; Cutress, R.I.; Greville-Heygate, S.; Altman, D.G.; Eccles, B.; Gerty, S.; Durcan, L.T.; Jones, L.; et al. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): A prospective cohort study. Lancet Oncol. 2018, 19, 169–180. [Google Scholar] [CrossRef] [Green Version]
  49. Veronesi, A.; de Giacomi, C.; Magri, M.D.; Lombardi, D.; Zanetti, M.; Scuderi, C.; Dolcetti, R.; Viel, A.; Crivellari, D.; Bidoli, E.; et al. Familial breast cancer: Characteristics and outcome of BRCA 1-2 positive and negative cases. BMC Cancer 2005, 5, 6. [Google Scholar] [CrossRef] [Green Version]
  50. Kwong, A.; Wong, L.P.; Wong, H.N.; Law, F.B.F.; Ng, E.K.O.; Tang, Y.H.; Chan, W.K.; Ho, L.S.; Kwan, K.H.; Poon, M.; et al. A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res. Treat. 2009, 117, 683–686. [Google Scholar] [CrossRef] [PubMed]
  51. Byrski, T.; Gronwald, J.; Huzarski, T.; Grzybowska, E.; Budryk, M.; Stawicka, M.; Mierzwa, T.; Szwiec, M.; Wisniowski, R.; Siolek, M.; et al. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res. Treat. 2008, 108, 289–296. [Google Scholar] [CrossRef] [PubMed]
  52. Musolino, A.; Bella, M.A.; Bortesi, B.; Michiara, M.; Naldi, N.; Zanelli, P.; Capelletti, M.; Pezzuolo, D.; Camisa, R.; Savi, M.; et al. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study. Breast 2007, 16, 280–292. [Google Scholar] [CrossRef] [PubMed]
  53. Roy, R.; Chun, J.; Powell, S.N. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat. Rev. Cancer 2012, 12, 68–78. [Google Scholar] [CrossRef] [Green Version]
  54. Winship, I.; Southey, M.C. Gene panel testing for hereditary breast cancer. Med. J. Aust. 2016, 204, 188–190. [Google Scholar] [CrossRef]
  55. Rebbeck, T.R.; Friebel, T.; Lynch, H.T.; Neuhausen, S.L.; van’t Veer, L.; Garber, J.E.; Evans, G.R.; Narod, S.A.; Isaacs, C.; Matloff, E.; et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: The PROSE study group. J. Clin. Oncol. 2004, 22, 1055–1062. [Google Scholar] [CrossRef] [Green Version]
  56. Metcalfe, K.A.; Lubinski, J.; Ghadirian, P.; Lynch, H.; Kim-Sing, C.; Friedman, E.; Foulkes, W.D.; Domchek, S.; Ainsworth, P.; Isaacs, C.; et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: The hereditary breast cancer clinical study group. J. Clin. Oncol. 2008, 26, 1093–1097. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  57. Metcalfe, K.; Gershman, S.; Ghadirian, P.; Lynch, H.T.; Snyder, C.; Tung, N.; Kim-Sing, C.; Eisen, A.; Foulkes, W.D.; Rosen, B.; et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: Retrospective analysis. Br. Med. J. 2014, 348, 11. [Google Scholar] [CrossRef] [Green Version]
  58. Smith, G.L. The Long and Short of Tamoxifen Therapy: A Review of the ATLAS Trial. J. Adv. Pract. Oncol. 2014, 5, 57–60. [Google Scholar] [PubMed]
  59. Chapppuis, P.O.; Goffin, J.; Wong, N.; Perret, C.; Ghadirian, P.; Tonin, P.N.; Foulkes, W.D. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J. Med. Genet. 2002, 39, 608–610. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  60. Kriege, M.; Seynaeve, C.; Meijers-Heijboer, H.; Collee, J.M.; Menke-Pluymers, M.B.E.; Bartels, C.C.M.; Tilanus-Linthorst, M.M.A.; Blom, J.; Huijskens, E.; Jager, A.; et al. Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers. J. Clin. Oncol. 2009, 27, 3764–3771. [Google Scholar] [CrossRef]
Biology 10 00566 g001 550
Figure 1. Kaplan Meier plots of survival analysis in carriers of BRCA1/2 pathogenic mutations and non-carriers. (a) Recurrence-free survival (RFS), (b) Metastasis-free survival (MFS), (c) Disease-free survival (DFS), (d) Overall survival (OS). p-values calculated by log-rank test (considering whole follow-up period).
Figure 1. Kaplan Meier plots of survival analysis in carriers of BRCA1/2 pathogenic mutations and non-carriers. (a) Recurrence-free survival (RFS), (b) Metastasis-free survival (MFS), (c) Disease-free survival (DFS), (d) Overall survival (OS). p-values calculated by log-rank test (considering whole follow-up period).
Biology 10 00566 g001
Biology 10 00566 g002 550
Figure 2. Kaplan Meier plots of survival analysis in carriers of all BRCA1/2 variants. (a) Disease-free survival (DFS), (b) Recurrence-free survival (RFS), (c) Overall survival (OS), (d) Metastasis-free survival (MFS). p-values calculated by log-rank test (considering whole follow-up period).
Figure 2. Kaplan Meier plots of survival analysis in carriers of all BRCA1/2 variants. (a) Disease-free survival (DFS), (b) Recurrence-free survival (RFS), (c) Overall survival (OS), (d) Metastasis-free survival (MFS). p-values calculated by log-rank test (considering whole follow-up period).
Biology 10 00566 g002
Biology 10 00566 g003 550
Figure 3. Kaplan Meier plots of survival analysis in carriers of BRCA1 and BRCA2 mutations independently and non-carriers. (a) Recurrence-free survival (RFS), (b) Metastasis-free survival (MFS), (c) Disease-free survival (DFS), (d) Overall survival (OS). p-values calculated by log-rank test (considering whole follow-up period).
Figure 3. Kaplan Meier plots of survival analysis in carriers of BRCA1 and BRCA2 mutations independently and non-carriers. (a) Recurrence-free survival (RFS), (b) Metastasis-free survival (MFS), (c) Disease-free survival (DFS), (d) Overall survival (OS). p-values calculated by log-rank test (considering whole follow-up period).
Biology 10 00566 g003
Table
Table 1. Clinicopathological characteristics of BRCA1/BRCA2 mutation carriers (together and separately) and non-carriers.
Table 1. Clinicopathological characteristics of BRCA1/BRCA2 mutation carriers (together and separately) and non-carriers.
FactorsBRCA1/2
(n = 29)		BRCA1
(n = 16)		BRCA2
(n = 16)		All BRCA1/2 Variants (n = 46)No BRCA Mutation (n = 57)
N (%)pN (%)pN (%)pN (%)pN (%)
Age at diagnosis
≤4014 (48)0.059 (56)0.0247 (44)0.1727 (59)0.00216 (28)
>4015 (52) 7 (44) 9 (56) 19 (41) 41 (72)
Median age at diagnosis
Year400.008400.006410.26400.00248
(range)(24–57)(24–61)(39–66) (24–63)(39–66)
Family history of cancer
Breast cancer
Other cancers13 (45)0.02410 (63)0.125 5 (31)0.00121 (46)0.00520 (35)
No10 (34)2 (12)9 (56)16 (34)9 (15)
6 (21)4 (25)2 (12)9 (20)28 (50)
Menopausal state
Premenopausal23 (79)0.0213 (81)0.0513 (81)0.0537 (80)0.00631 (54)
Postmenopausal6 (21)3 (19)3 (19)9 (20)26 (46)
Tumor size
T1–T220 (69)0.713 (81)0.459 (56)0.227 (59)0.0241 (72)
T3–T49 (31)3 (19)7 (44)19 (41)16 (28)
Lymph node involvement
Negative
positive7 (24)0.0310 (62)0.42 (12)0.01210 (22)0.00727 (47)
22 (76)6 (38)14 (88)36 (78)30 (53)
Histological grade
G10 0 0 0 0
G228 (96.6)0.6215 (94)0.3316 (100)0.5944 (97)0.3556 (98)
G31 (3.4) 1 (6) 0 (0) 2 (3) 1 (2)
Histological type
Ductal25 (86.2) 13 (81) 15 (94) 42 (91) 54 (95)
Lobular3 (10.3)0.242 (13)0.451 (6)0.93 (7)0.53 (5)
Mixed 1 (3.5) 1 (6) 0 1 (2) 0
ER status
Positive 21 (72)0.4912 (75)0.8510 (63)0.2330 (65)0.1745 (78)
Negative8 (28)4 (25)6 (37)16 (35)12 (22)
PR status
Positive 18 (62)0.4411 (69)0.98 (50)0.1326 (57)0.1540 (70)
Negative11 (38)5 (31)8 (50)20 (43)17 (30)
HER2 status
Positive 6 (24)0.293 (23)0.54 (29)0.414 (35)0.214 (33)
Negative19 (76)10 (77)10 (71)26 (65)28 (67)
Not available432615
Laterality
Unilateral24 (83)0.214 (88)0.2513 (81)0.2535 (76)0.00752 (91)
Bilateral 5 (17)2 (12)3 (19)11 (24)5 (9)
T, tumor size; G, grade; ER, estrogen receptor; PR, progesterone receptor; Her-2, human epidermal growth factor receptor 2; Bold, statistically significant differences as compared to BRCA1/2 non-carriers.
Table
Table 2. Univariate analysis for disease-free survival (DFS).
Table 2. Univariate analysis for disease-free survival (DFS).
FactorsNumber of CasesNumber of EventsDFS % 1 YearMedianp-Value
Age, years≤40 437124.34.90.41
>40 603323.84.7
MenopausePost353824.45.30.16
Pre682042.25.3
NursingNo355118.84.70.68
Yes682318.85.3
Hormonal contraceptiveNo364826.04.70.83
Yes672534.65.7
ERNegative294318.35.30.02
Positive742218.33.9
PRNegative374927.75.80.03
Positive662920.84.4
HER-2Negative534231.45.80.80
Positive29386.84.5
Lymph nodeN037200.04.00.74
N1662526.15.3
T-stageT1-T2684622.95.00.012
T3-T4352245.730.5
LateralityBilateral161625.012.5<0.001
Unilateral872965.565.5
Family historyNo402329.45.70.29
Yes634720.04.4
BRCA1/2Carrier 463213.24.20.024
Non-carrier573931.55.8
Bold: statistically significant.
Table
Table 3. Survival outcomes in patients harboring BRCA1 mutation c.5205delA (p.Val1736Serfs*29) as compared to non-carriers.
Table 3. Survival outcomes in patients harboring BRCA1 mutation c.5205delA (p.Val1736Serfs*29) as compared to non-carriers.
OutcomeMutation StatusNo. of CasesNo.of Events%2 yrs%5 yrs%10 yrsp-Value
RFSMut carrier16610067.760.20.740
Noncarrier571798.284.060.1
MFSMut carrier161110042.228.10.462
Noncarrier573487.762.738.4
DFSMut carrier1612100.042.221.10.403
Noncarrier573787.764.634.0
OSMut carrier164100.086.775.80.582
Noncarrier5718100.094.060.6
RFS: Recurrence-free survival, MFS: Metastasis-free survival, DFS: Disease-free survival, OS: Overall survival.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

AbdelHamid, S.; El-Mesallamy, H.; Aziz, H.A.; Zekri, A.-R. Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients. Biology 2021, 10, 566. https://doi.org/10.3390/biology10070566

AMA Style

AbdelHamid S, El-Mesallamy H, Aziz HA, Zekri A-R. Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients. Biology. 2021; 10(7):566. https://doi.org/10.3390/biology10070566

Chicago/Turabian Style

AbdelHamid, Sherihan, Hala El-Mesallamy, Hany Abdel Aziz, and Abdel-Rahman Zekri. 2021. "Prognostic Impact of BRCA1 and BRCA2 Mutations on Long-Term Survival Outcomes in Egyptian Female Breast Cancer Patients" Biology 10, no. 7: 566. https://doi.org/10.3390/biology10070566

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop